Literature DB >> 28539442

Extracellular Interactions between Hepatitis C Virus and Secreted Apolipoprotein E.

Zhihua Li1,2,3, Yadong Li1,2, Yanwei Bi1,2,3, Hui Zhang1,2, Yufeng Yao1,2, Qihan Li1,2, Wei Cun4,2,3, Shaozhong Dong4,2.   

Abstract

Interactions between hepatitis C virus (HCV) and lipoproteins in humans play an important role in the efficient establishment of chronic infection. Apolipoprotein E (ApoE) on the HCV envelope mediates virus attachment to host cells as well as immune evasion. This interaction is thought to occur in hepatocytes, as ApoE plays dual functions in HCV assembly and maturation as well as cell attachment. In the present study, we found that secreted ApoE (sApoE) can also bind to viral particles via its C-terminal domain after HCV is released from the cell. Furthermore, the binding affinity of interactions between the sApoE N terminus and cell surface receptors affected HCV infectivity in a dose-dependent manner. The extracellular binding of sApoE to HCV is dependent on HCV envelope proteins, and recombinant HCV envelope proteins are also able to bind to sApoE. These results suggest that extracellular interactions between HCV and sApoE may potentially complicate vaccine development and studies of viral pathogenesis.IMPORTANCE End-stage liver disease caused by chronic HCV infection remains a clinical challenge, and there is an urgent need for a prophylactic method of controlling HCV infection. Because host immunity against HCV is poorly understood, additional investigations of host-virus interactions in the context of HCV are important. HCV is primarily transmitted through blood, which is rich in lipoproteins. Therefore, it is of interest to further determine how HCV interacts with lipoproteins in human blood. In this study, we found that secreted ApoE (sApoE), an exchangeable component found in lipoproteins, participates in extracellular interactions with HCV virions. More significantly, different variants of sApoE differentially affect HCV infection efficiency in a dose-dependent manner. These findings provide greater insight into HCV infection and host immunity and could help propel the development of new strategies for preventing HCV infection.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  CRISPR-Cas9; envelope protein; hepatitis C virus; infectivity; secreted apolipoprotein E

Mesh:

Substances:

Year:  2017        PMID: 28539442      PMCID: PMC5512249          DOI: 10.1128/JVI.02227-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes.

Authors:  Budhaditya Mazumdar; Arup Banerjee; Keith Meyer; Ranjit Ray
Journal:  Hepatology       Date:  2011-07-25       Impact factor: 17.425

2.  Apolipoprotein E likely contributes to a maturation step of infectious hepatitis C virus particles and interacts with viral envelope glycoproteins.

Authors:  Ji-Young Lee; Eliana G Acosta; Ina Karen Stoeck; Gang Long; Marie-Sophie Hiet; Birthe Mueller; Oliver T Fackler; Stephanie Kallis; Ralf Bartenschlager
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

3.  Dengue virus isolation by antibody-dependent enhancement of infectivity in macrophages.

Authors:  M J Cardosa
Journal:  Lancet       Date:  1987-01-24       Impact factor: 79.321

4.  Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding.

Authors:  Shufeng Liu; Kevin D McCormick; Wentao Zhao; Ting Zhao; Daping Fan; Tianyi Wang
Journal:  Hepatology       Date:  2012-07-02       Impact factor: 17.425

Review 5.  Pathogenesis of dengue: challenges to molecular biology.

Authors:  S B Halstead
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

6.  Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture.

Authors:  Kyung-Soo Chang; Jieyun Jiang; Zhaohui Cai; Guangxiang Luo
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

7.  Carriage of the apolipoprotein E-epsilon4 allele and histologic outcome of recurrent hepatitis C after antiviral treatment.

Authors:  Pierluigi Toniutto; Carlo Fabris; Elisabetta Fumo; Luca Apollonio; Maya Caldato; Laura Mariuzzi; Claudio Avellini; Rosalba Minisini; Mario Pirisi
Journal:  Am J Clin Pathol       Date:  2004-09       Impact factor: 2.493

8.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

9.  Expression and identification of hepatitis C virus polyprotein cleavage products.

Authors:  A Grakoui; C Wychowski; C Lin; S M Feinstone; C M Rice
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

10.  The natural history of hepatitis C virus (HCV) infection.

Authors:  Stephen L Chen; Timothy R Morgan
Journal:  Int J Med Sci       Date:  2006-04-01       Impact factor: 3.738

View more
  8 in total

1.  Host-derived apolipoproteins play comparable roles with viral secretory proteins Erns and NS1 in the infectious particle formation of Flaviviridae.

Authors:  Takasuke Fukuhara; Tomokazu Tamura; Chikako Ono; Mai Shiokawa; Hiroyuki Mori; Kentaro Uemura; Satomi Yamamoto; Takeshi Kurihara; Toru Okamoto; Ryosuke Suzuki; Kentaro Yoshii; Takeshi Kurosu; Manabu Igarashi; Hiroshi Aoki; Yoshihiro Sakoda; Yoshiharu Matsuura
Journal:  PLoS Pathog       Date:  2017-06-23       Impact factor: 6.823

Review 2.  Hepatitis C Virus (HCV)-Apolipoprotein Interactions and Immune Evasion and Their Impact on HCV Vaccine Design.

Authors:  Florian Wrensch; Emilie Crouchet; Gaetan Ligat; Mirjam B Zeisel; Zhen-Yong Keck; Steven K H Foung; Catherine Schuster; Thomas F Baumert
Journal:  Front Immunol       Date:  2018-06-21       Impact factor: 8.786

Review 3.  HCV Pit Stop at the Lipid Droplet: Refuel Lipids and Put on a Lipoprotein Coat before Exit.

Authors:  Gabrielle Vieyres; Thomas Pietschmann
Journal:  Cells       Date:  2019-03-12       Impact factor: 6.600

4.  Human apolipoprotein E promotes hepatitis B virus infection and production.

Authors:  Luhua Qiao; Guangxiang George Luo
Journal:  PLoS Pathog       Date:  2019-08-08       Impact factor: 6.823

5.  The Effect of Treatment-Induced Viral Eradication on Cytokine and Growth Factor Expression in Chronic Hepatitis C.

Authors:  Leona Radmanić; Kristian Bodulić; Petra Šimičić; Adriana Vince; Snježana Židovec Lepej
Journal:  Viruses       Date:  2022-07-24       Impact factor: 5.818

6.  Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.

Authors:  John L M Law; Michael Logan; Jason Wong; Juthika Kundu; Darren Hockman; Amir Landi; Chao Chen; Kevin Crawford; Mark Wininger; Janelle Johnson; Catalina Mesa Prince; Elzbieta Dudek; Ninad Mehta; D Lorne Tyrrell; Michael Houghton
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

7.  The ATGL lipase cooperates with ABHD5 to mobilize lipids for hepatitis C virus assembly.

Authors:  Gabrielle Vieyres; Isabelle Reichert; Arnaud Carpentier; Florian W R Vondran; Thomas Pietschmann
Journal:  PLoS Pathog       Date:  2020-06-15       Impact factor: 6.823

Review 8.  Delayed by Design: Role of Suboptimal Signal Peptidase Processing of Viral Structural Protein Precursors in Flaviviridae Virus Assembly.

Authors:  Nabeel Alzahrani; Ming-Jhan Wu; Saravanabalaji Shanmugam; MinKyung Yi
Journal:  Viruses       Date:  2020-09-26       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.